Stocks & Investing
Fri, October 4, 2024
[ Fri, Oct 04th 2024
] - WOPRAI
Thu, August 15, 2024
[ Thu, Aug 15th 2024
] - WOPRAI
Thu, August 8, 2024
[ Thu, Aug 08th 2024
] - WOPRAI
Wed, August 7, 2024
[ Wed, Aug 07th 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
Mon, August 5, 2024
[ Mon, Aug 05th 2024
] - WOPRAI
Fri, August 2, 2024
[ Fri, Aug 02nd 2024
] - WOPRAI
[ Fri, Aug 02nd 2024
] - WOPRAI
Tue, June 25, 2024
[ Tue, Jun 25th 2024
] - WOPRAI
Fri, June 21, 2024
[ Fri, Jun 21st 2024
] - WOPRAI
Wed, May 8, 2024
[ Wed, May 08th 2024
] - WOPRAI
Thu, February 29, 2024
[ Thu, Feb 29th 2024
] - WOPRAI
Wed, February 28, 2024
[ Wed, Feb 28th 2024
] - WOPRAI
Tue, February 6, 2024
[ Tue, Feb 06th 2024
] - WOPRAI
Mon, December 11, 2023
[ Mon, Dec 11th 2023
] - WOPRAI
Thu, November 2, 2023
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
Wed, August 9, 2023
[ Wed, Aug 09th 2023
] - WOPRAI
Wed, August 2, 2023
[ Wed, Aug 02nd 2023
] - WOPRAI
Fri, July 21, 2023
[ Fri, Jul 21st 2023
] - WOPRAI
Thu, June 1, 2023
[ Thu, Jun 01st 2023
] - WOPRAI
Thu, May 11, 2023
[ Thu, May 11th 2023
] - WOPRAI
Tue, May 2, 2023
[ Tue, May 02nd 2023
] - WOPRAI
Wed, February 8, 2023
[ Wed, Feb 08th 2023
] - WOPRAI
Thu, December 22, 2022
[ Thu, Dec 22nd 2022
] - WOPRAI
Wed, November 2, 2022
[ Wed, Nov 02nd 2022
] - WOPRAI
Fri, October 28, 2022
[ Fri, Oct 28th 2022
] - WOPRAI
[ Fri, Oct 28th 2022
] - WOPRAI
Wed, August 10, 2022
[ Wed, Aug 10th 2022
] - WOPRAI
Gena Wang Maintained (BMRN) at Buy with Decreased Target to $86 on, Oct 4th, 2024
Gena Wang of Barclays, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $110 to $86 on, Oct 4th, 2024.
Gena has made no other calls on BMRN in the last 4 months.
There are 12 other peers that have a rating on BMRN. Out of the 12 peers that are also analyzing BMRN, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- George Farmer of "Scotiabank" Maintained at Hold with Decreased Target to $78 on, Tuesday, September 17th, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $93 on, Friday, September 13th, 2024
These are the ratings of the 10 analyists that currently disagree with Gena
- Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $115 on, Tuesday, September 17th, 2024
- Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $90 on, Tuesday, September 17th, 2024
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Decreased Target to $90 on, Tuesday, September 17th, 2024
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $87 on, Tuesday, September 17th, 2024
- William Pickering of "Bernstein" Maintained at Buy with Decreased Target to $90 on, Tuesday, September 17th, 2024
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, September 9th, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $120 on, Thursday, September 5th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $122 on, Thursday, September 5th, 2024
- Cory Kasimov of "Evercore ISI Group" Maintained at Buy with Increased Target to $115 on, Tuesday, August 6th, 2024
- Phil Nadeau of "TD Cowen" Maintained at Strong Buy with Decreased Target to $120 on, Tuesday, August 6th, 2024
